MCID: TRD006
MIFTS: 47

Tardive Dyskinesia malady

Rare diseases, Neuronal diseases, Oral diseases categories

Aliases & Classifications for Tardive Dyskinesia

About this section

Tardive Dyskinesia, Aliases & Descriptions:

Name: Tardive Dyskinesia 41 42 60
Neuroleptic-Induced Tardive Dyskinesia 60
Lingual-Facial-Buccal Dyskinesia 60
Linguofacial Dyskinesia 41
 
Tardive Oral Dyskinesia 41
Tardive Dystonia 41
Td 41


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases
Anatomical: Neuronal diseases, Oral diseases


Summaries for Tardive Dyskinesia

About this section


NIH Rare Diseases:41 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. it is unclear why some people who take neuroleptic medications develop these symptoms while others do not. treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms. last updated: 12/18/2014

MalaCards based summary: Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to schizophrenia and mood disorder, and has symptoms including autosomal recessive inheritanceand abnormality of the nervous system. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H dehydrogenase, quinone 1), and among its related pathways are AHR Pathway and Estrogen metabolism. The compounds nemonapride and eticlopride have been mentioned in the context of this disorder. Affiliated tissues include tongue, eye and brain, and related mouse phenotypes are homeostasis/metabolism and behavior/neurological.

NINDS:42 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia:63 Tardive dyskinesia /?t?rd?v ?d?sk??ni???/ is a difficult-to-treat and often incurable form of... more...

Related Diseases for Tardive Dyskinesia

About this section

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 56)
idRelated DiseaseScoreTop Affiliating Genes
1schizophrenia31.5DRD3, DRD4, CYP2D6
2mood disorder30.5DRD1, DRD3, DRD4
3gilles de la tourette syndrome30.2DRD1, DRD3, DRD4
4hepatitis30.0CYP2D6, HSPG2, CYP1A2
5bipolar disorder29.9DRD3, HSPG2, DRD4, DRD1
6blindness10.7
7dystonia10.6
8delusional disorder10.3DRD4
9neuronitis10.3
10dementia10.3
11hypothyroidism10.3
12drug induced dyskinesia10.3
13neuroleptic malignant syndrome10.2CYP2D6
14huntington disease10.2
15cataract10.2
16myelitis10.2
17anosognosia10.2
18blepharospasm10.2
19olecranon bursitis10.2
20rocky mountain spotted fever10.2
21cerebritis10.2
22bipolar i disorder10.2
23bursitis10.2
24cervicitis10.2
25megacolon10.2
26spotted fever10.2
27developmental disabilities10.2
28childhood-onset schizophrenia10.2
29back pain10.2
30dysphagia10.2
31endotheliitis10.2
32diffuse idiopathic skeletal hyperostosis10.2
33cervical dystonia10.2
34hyperostosis10.2
35spasmodic dysphonia10.2
36drug addiction10.1DRD3, DRD1
37personality disorder10.1DRD3, DRD4
38substance dependence10.1DRD4, DRD3
39heroin dependence10.1ANKK1, DRD4
40nicotine dependence, protection against10.1NQO1, CYP1A2
41substance abuse10.1DRD3, DRD4
42parkinson disease, late-onset10.1CYP2D6, DRD3
43pathological gambling9.9DRD1, DRD4, DRD3
44obsessive-compulsive disorder9.9DRD1, DRD4, DRD3
45movement disease9.9CYP2D6, DRD3
46alcohol dependence9.9DRD1, DRD3, DRD4
47attention deficit-hyperactivity disorder9.9DRD1, DRD4
48autoimmune hepatitis9.9CYP2D6, HSPG2, CYP1A2
49aplastic anemia9.8CYP2D6, NQO1
50bladder cancer, somatic9.8NQO1, CYP2D6, CYP1A2

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to tardive dyskinesia

Symptoms for Tardive Dyskinesia

About this section

HPO human phenotypes related to Tardive Dyskinesia:

id Description Frequency HPO Source Accession
1 autosomal recessive inheritance HP:0000007
2 abnormality of the nervous system HP:0000707

Drugs & Therapeutics for Tardive Dyskinesia

About this section

Drug clinical trials:

Search ClinicalTrials for Tardive Dyskinesia

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

About this section

Anatomical Context for Tardive Dyskinesia

About this section

MalaCards organs/tissues related to Tardive Dyskinesia:

31
Tongue, Eye, Brain, Globus pallidus, Cortex, Testes, Endothelial

Animal Models for Tardive Dyskinesia or affiliated genes

About this section

MGI Mouse Phenotypes related to Tardive Dyskinesia:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.7NQO1, HSPG2, DRD4, DRD3, DRD1, CYP1A2
2MP:00053867.4SIGMAR1, DRD1, DRD3, DRD4, HSPG2, CYP1A2

Publications for Tardive Dyskinesia

About this section

Articles related to Tardive Dyskinesia:

(show top 50)    (show all 554)
idTitleAuthorsYear
1
Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. (25602162)
2015
2
Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. (24389397)
2014
3
Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. (25378945)
2014
4
Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. (24995685)
2014
5
Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. (25142102)
2014
6
Structural brain changes associated with tardive dyskinesia in schizophrenia. (23222039)
2013
7
The relevance of EEG artifact identification: a case of "delta-wave blinking" due to tardive dyskinesia. (23422518)
2013
8
New and emerging treatments for symptomatic tardive dyskinesia. (24235816)
2013
9
Tardive dyskinesia in schizophrenia. (23818532)
2013
10
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study. (23666822)
2013
11
Aquaporin-4 knockout abolishes apomorphine-induced tardive dyskinesia following chronic treatment with neuroleptics. (23126383)
2012
12
Tetrabenazine for the treatment of tardive dyskinesia. (21487088)
2011
13
Tardive dyskinesia. (21365202)
2011
14
Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes. (21816389)
2011
15
Tardive dyskinesia: treatment with aripiprazole. (23430384)
2011
16
Rational antipsychotic choice: weighing the risk of tardive dyskinesia and metabolic syndrome. (21916828)
2011
17
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. (20816031)
2011
18
Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. (20436352)
2010
19
Dysphagia due to tardive dyskinesia. (22174539)
2010
20
Rapid improvement of neuroleptic-induced tardive dyskinesia with levetiracetam in an interictal psychotic patient. (20520300)
2010
21
Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. (20369355)
2010
22
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. (19238168)
2009
23
MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis. (19282152)
2009
24
Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia. (21686897)
2009
25
Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. (18548510)
2009
26
Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms. (18433967)
2008
27
Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. (18759358)
2008
28
Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. (17669630)
2007
29
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. (18162021)
2007
30
Tardive dyskinesia circa 2006. (16877639)
2006
31
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. (16319911)
2006
32
Focus on lower risk of tardive dyskinesia with atypical antipsychotics. (16517454)
2006
33
The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. (16769201)
2006
34
Improvement in tardive dyskinesia with aripiprazole use. (15830835)
2005
35
Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. (15836802)
2005
36
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. (16363464)
2005
37
Tardive dyskinesia after long-term veralipride treatment. (15939983)
2005
38
Risperidone and olanzapine induced tardive dyskinesia : a critical review of reported cases. (21206790)
2004
39
Tardive dyskinesia in 2 patients treated with ziprasidone. (15644988)
2004
40
Mu opioid receptor gene polymorphism and neuroleptic-induced tardive dyskinesia in patients with schizophrenia. (14623376)
2003
41
Treatment-emergent tardive dyskinesia with quetiapine in mood disorders. (12920421)
2003
42
Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. (12960753)
2003
43
Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. (12669107)
2003
44
Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. (12177588)
2002
45
Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari Hospital, Nairobi. (12635762)
2002
46
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. (12172349)
2002
47
Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. (12057822)
2002
48
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. (11496364)
2001
49
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. (11317227)
2001
50
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. (10379516)
1999

Variations for Tardive Dyskinesia

About this section

Expression for genes affiliated with Tardive Dyskinesia

About this section
Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for genes affiliated with Tardive Dyskinesia

About this section

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
AhR pathway36
9.6NQO1, CYP1A2
2
Show member pathways
9.6NQO1, CYP1A2
39.3DRD4, DRD1
4
Show member pathways
Retinol metabolism58
9.1CYP1A2, CYP2D6
59.1CYP2D6, CYP1A2
6
Show member pathways
9.1CYP1A2, CYP2D6
7
Show member pathways
9.1CYP2D6, CYP1A2
8
Show member pathways
Nicotine Activity on Dopaminergic Neurons36
8.9DRD1, DRD3, DRD4
9
Show member pathways
8.9DRD1, DRD3, DRD4
10
Show member pathways
8.9DRD1, DRD3, DRD4
118.9DRD4, DRD3, DRD1
12
Show member pathways
8.8NQO1, CYP1A2, CYP2D6
13
Show member pathways
8.1CYP2D6, DRD4, DRD3, DRD1

Compounds for genes affiliated with Tardive Dyskinesia

About this section

Compounds related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show top 50)    (show all 278)
idCompoundScoreTop Affiliating Genes
1nemonapride43 49 2811.3DRD3, ANKK1, DRD4
2eticlopride43 2810.3DRD1, DRD4, DRD3
3(+)-butaclamol43 2810.3DRD1, DRD4, DRD3
4sch 23390439.3DRD3, DRD1, DRD4
5raclopride43 2810.2DRD3, DRD4, DRD1
6spiperone43 2810.2DRD4, DRD3, DRD1
7sulpiride43 28 1211.1DRD3, DRD1, DRD4
8duloxetine43 49 28 1212.0CYP1A2, DRD3, CYP2D6
9dextromethorphan2 49 24 1212.0SIGMAR1, CYP1A2, CYP2D6
10promazine43 1210.0DRD1, DRD4, CYP1A2
116-hydroxydopamine439.0NQO1, DRD1, DRD3, DRD4
12thiothixene28 129.9CYP1A2, DRD1, CYP2D6
13pramipexole43 28 49 1211.9DRD4, DRD1, DRD3
14pimozide28 43 49 1211.9CYP1A2, DRD3, CYP2D6
15piperazine43 129.9CYP2D6, DRD4, DRD3
16quinpirole43 289.8DRD3, DRD4, DRD1
17chlorzoxazone43 28 1210.8CYP2D6, CYP1A2, NQO1
18bromocriptine43 28 1210.8DRD1, DRD3, DRD4, CYP1A2
19methylphenidate43 49 1210.7DRD4, DRD1, CYP2D6
20thioridazine28 43 49 1211.7CYP1A2, DRD1, CYP2D6
21antipsychotics498.7CYP2D6, HSPG2, ANKK1, CYP1A2
22remoxipride43 129.7DRD3, SIGMAR1, CYP2D6, DRD4
23perphenazine28 43 49 1211.7CYP1A2, CYP2D6, DRD1
24bupropion49 43 24 1211.7ANKK1, CYP1A2, DRD3, CYP2D6
25cabergoline43 28 1210.6DRD1, DRD3, DRD4
26domperidone43 28 1210.6CYP2D6, DRD1, CYP1A2, DRD3
27imipramine43 28 49 24 1212.5CYP2D6, DRD3, DRD1, CYP1A2
28lisuride43 28 1210.5DRD1, DRD3, DRD4, CYP2D6
29pergolide43 28 1210.5DRD4, DRD3, CYP2D6, DRD1
30aripiprazole28 43 49 24 1212.5DRD1, DRD3, CYP2D6, DRD4
31paroxetine43 49 28 1211.5CYP2D6, DRD4, CYP1A2, DRD3
32quetiapine43 49 28 24 1212.5CYP2D6, DRD4, DRD3, DRD1
33methamphetamine43 49 1210.5DRD1, DRD3, DRD4, CYP2D6
34fluphenazine28 43 49 1211.4CYP2D6, DRD1, CYP1A2, DRD4
35levodopa43 129.4CYP2D6, DRD4, DRD1, DRD3
36norepinephrine43 24 1210.4DRD1, DRD4, DRD3, CYP1A2, NQO1
37cocaine43 129.1DRD3, CYP2D6, DRD4, SIGMAR1, DRD1
38risperidone43 49 28 59 24 1213.1ANKK1, CYP2D6, DRD3, DRD4, DRD1
39rotigotine28 43 1210.0DRD4, DRD3, CYP1A2, CYP2D6, DRD1
40ropinirole43 129.0DRD1, DRD3, DRD4, CYP1A2, CYP2D6
41paliperidone43 129.0CYP1A2, DRD1, DRD4, DRD3, CYP2D6
42iloperidone49 43 28 1211.0CYP2D6, CYP1A2, DRD4, DRD3, DRD1
43asenapine28 129.0CYP1A2, DRD1, DRD4, DRD3, CYP2D6
44ziprasidone28 49 43 1211.0CYP1A2, DRD4, DRD3, DRD1, CYP2D6
45chlorpromazine28 43 49 1211.0DRD1, DRD4, CYP1A2, CYP2D6, DRD3
46haloperidol43 49 28 2 1211.7CYP1A2, DRD4, DRD3, DRD1, SIGMAR1, CYP2D6
47olanzapine43 49 28 24 1211.6CYP2D6, DRD1, CYP1A2, ANKK1, DRD4, DRD3
48clozapine43 28 49 1210.6DRD3, DRD4, ANKK1, CYP1A2, DRD1, CYP2D6
49nicotine43 28 49 1210.5DRD3, DRD4, CYP1A2, DRD1, ANKK1, CYP2D6
50dopamine43 28 24 1210.3DRD3, SIGMAR1, DRD1, DRD4, NQO1, CYP2D6

GO Terms for genes affiliated with Tardive Dyskinesia

About this section

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of plasma membraneGO:00058878.6SIGMAR1, DRD1, DRD3, DRD4
2endoplasmic reticulum membraneGO:00057898.0SIGMAR1, DRD1, CYP1A2, CYP2D6

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1regulation of dopamine uptake involved in synaptic transmissionGO:00515849.9DRD1, DRD3
2adenylate cyclase-activating dopamine receptor signaling pathwayGO:00071919.8DRD3, DRD1
3response to histamineGO:00347769.8DRD3, DRD4
4adenylate cyclase-inhibiting dopamine receptor signaling pathwayGO:00071959.7DRD4, DRD3
5prepulse inhibitionGO:00601349.7DRD3, DRD1
6negative regulation of protein secretionGO:00507099.6DRD3, DRD4
7regulation of dopamine metabolic processGO:00420539.6DRD1, DRD4
8arachidonic acid secretionGO:00504829.6DRD3, DRD4
9visual learningGO:00085429.5DRD1, DRD3
10negative regulation of adenylate cyclase activityGO:00071949.5DRD4, DRD3
11alkaloid metabolic processGO:00098209.5CYP2D6, CYP1A2
12drug catabolic processGO:00427379.4CYP2D6, CYP1A2
13heterocycle metabolic processGO:00464839.4CYP2D6, CYP1A2
14monoterpenoid metabolic processGO:00160989.4CYP2D6, CYP1A2
15oxidative demethylationGO:00709899.4CYP1A2, CYP2D6
16behavioral fear responseGO:00016629.3DRD4, DRD1
17dopamine metabolic processGO:00424179.3DRD1, DRD3, DRD4
18synaptic transmission, dopaminergicGO:00019639.3DRD1, DRD3, DRD4
19behavioral response to cocaineGO:00481489.3DRD4, DRD3, DRD1
20response to amphetamineGO:00019759.3DRD1, DRD3, DRD4
21social behaviorGO:00351769.1DRD3, DRD4
22drug metabolic processGO:00171449.0CYP1A2, CYP2D6
23xenobiotic metabolic processGO:00068059.0NQO1, CYP1A2, CYP2D6

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine neurotransmitter receptor activity, coupled via Gi/GoGO:00015919.3DRD4, DRD3
2dopamine neurotransmitter receptor activityGO:00049529.3DRD4, DRD1
3monooxygenase activityGO:00044979.1CYP1A2, CYP2D6
4dopamine bindingGO:00352409.0DRD1, DRD3, DRD4
5aromatase activityGO:00703308.8CYP1A2, CYP2D6
6drug bindingGO:00081448.4SIGMAR1, DRD3, DRD4, CYP2D6

Products for genes affiliated with Tardive Dyskinesia

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Tardive Dyskinesia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet